Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-Biotherapy (Ipilimumab + Interferon + IL-2) in Metastatic Melanoma
NCT01409187Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2011
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Planned start Oct 2011; status: withdrawn.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01409187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01409187.